Technical Analysis for ADPT - Adaptive Biotechnologies Corporation

Grade Last Price % Change Price Change
grade C 30.2 -4.64% -1.47
ADPT closed down 4.64 percent on Friday, December 13, 2019, on 1.44 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Up Up
See historical ADPT trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
Slingshot Bullish Bullish Swing Setup 0.00%
Stochastic Reached Overbought Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bullish Other 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Pocket Pivot Bullish Swing Setup -4.64%
Upper Bollinger Band Walk Strength -4.64%
Above Upper BB Strength -4.64%
Older signals for ADPT ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Cancer Diseases Infectious Diseases Cancers Drug Discovery Diagnostic Tests Leukemia

Is ADPT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 55.1203
52 Week Low 24.05
Average Volume 524,798
200-Day Moving Average 0.00
50-Day Moving Average 28.28
20-Day Moving Average 28.79
10-Day Moving Average 29.02
Average True Range 1.93
ADX 18.74
+DI 26.54
-DI 13.89
Chandelier Exit (Long, 3 ATRs ) 26.19
Chandelier Exit (Short, 3 ATRs ) 31.90
Upper Bollinger Band 31.18
Lower Bollinger Band 26.41
Percent B (%b) 0.8
BandWidth 16.56
MACD Line 0.39
MACD Signal Line 0.02
MACD Histogram 0.3767
Fundamentals Value
Market Cap 3.64 Billion
Num Shares 120 Million
EPS -0.15
Price-to-Earnings (P/E) Ratio -206.85
Price-to-Sales 4.89
Price-to-Book 0.91
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 33.70
Resistance 3 (R3) 33.84 32.82 33.12
Resistance 2 (R2) 32.82 31.93 32.75 32.92
Resistance 1 (R1) 31.51 31.38 31.00 31.37 32.73
Pivot Point 30.48 30.48 30.23 30.41 30.48
Support 1 (S1) 29.18 29.59 28.66 29.03 27.67
Support 2 (S2) 28.15 29.04 28.08 27.48
Support 3 (S3) 26.84 28.15 27.28
Support 4 (S4) 26.70